Badalona

• An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended recruitment
  2024-517006-28-00 9 2021-11-23 Multiple myeloma
• Study of Nivolumab and Ipilimumab plus chemotherapy as a treatment for patients with stage IV lung cancer with brain metastases. Ended recruitment
  2024-513866-20-00 4 2021-11-18 Non-small cell lung cancer with brain metastasis
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas … Ended recruitment
  2023-510319-20-00 5 2021-10-21 Gastroesophageal Adenocarcinoma (GEA)
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combina … Ended recruitment
  2023-510307-22-00 1 2021-09-24 Advanced head and neck cancer
• A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects … Ended recruitment
  2023-506094-35-00 3 2021-09-17 Newly diagnosed aggressive B-cell lymphoma (a-BCL)
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Ended recruitment
  2024-512038-13-00 5 2021-09-16 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended recruitment
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A … Ended recruitment
  2023-507963-20-00 5 2021-08-19 Metastatic Gastric Adenocarcinoma
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll … Ended recruitment
  2024-511321-54-00 5 2021-08-04 intermediate-high-risk acute pulmonary embolism
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended recruitment
  2023-508738-32-00 4 2021-06-16 Previously untreated and histologically confirmed HER2-Positive (HER2
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended recruitment
  2024-511753-22-00 5 2021-05-26 Primary Biliary Cholangitis
• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St … Ended recruitment
  2023-508372-10-00 4 2021-05-19 Non small Cell Lung cancer
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended recruitment
  2023-505615-21-00 5 2021-04-28 Muscle Invasive Bladder Cancer
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog … Ended recruitment
  2023-506498-36-00 5 2021-04-08 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• Inebilizumab efficacy and safety in adults with myasthenia gravis Ended recruitment
  2023-510006-40-00 5 2021-03-22 Myasthenia Gravis which is either due to acetylcholine receptor antibo

Showing 505–528 of 775 trials